ALGN vs. WST, COO, ZBH, SNN, MSA, XRAY, MMSI, HAE, WMGI, and NEOG
Should you be buying Align Technology stock or one of its competitors? The main competitors of Align Technology include West Pharmaceutical Services (WST), Cooper Companies (COO), Zimmer Biomet (ZBH), Smith & Nephew (SNN), MSA Safety (MSA), DENTSPLY SIRONA (XRAY), Merit Medical Systems (MMSI), Haemonetics (HAE), Wright Medical Group (WMGI), and Neogen (NEOG).
West Pharmaceutical Services (NYSE:WST) and Align Technology (NASDAQ:ALGN) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, community ranking, earnings, dividends, analyst recommendations, valuation and media sentiment.
West Pharmaceutical Services has higher earnings, but lower revenue than Align Technology. West Pharmaceutical Services is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.
Align Technology received 502 more outperform votes than West Pharmaceutical Services when rated by MarketBeat users. Likewise, 69.58% of users gave Align Technology an outperform vote while only 55.74% of users gave West Pharmaceutical Services an outperform vote.
In the previous week, Align Technology had 7 more articles in the media than West Pharmaceutical Services. MarketBeat recorded 11 mentions for Align Technology and 4 mentions for West Pharmaceutical Services. Align Technology's average media sentiment score of 1.73 beat West Pharmaceutical Services' score of 1.21 indicating that West Pharmaceutical Services is being referred to more favorably in the media.
West Pharmaceutical Services has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500. Comparatively, Align Technology has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500.
93.9% of West Pharmaceutical Services shares are held by institutional investors. Comparatively, 88.4% of Align Technology shares are held by institutional investors. 0.5% of West Pharmaceutical Services shares are held by company insiders. Comparatively, 0.6% of Align Technology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
West Pharmaceutical Services has a net margin of 19.42% compared to West Pharmaceutical Services' net margin of 11.80%. Align Technology's return on equity of 20.57% beat West Pharmaceutical Services' return on equity.
West Pharmaceutical Services presently has a consensus price target of $435.20, indicating a potential upside of 38.26%. Align Technology has a consensus price target of $353.00, indicating a potential upside of 38.14%. Given Align Technology's stronger consensus rating and higher possible upside, equities research analysts plainly believe West Pharmaceutical Services is more favorable than Align Technology.
Summary
West Pharmaceutical Services beats Align Technology on 10 of the 18 factors compared between the two stocks.
Get Align Technology News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Align Technology Competitors List
Related Companies and Tools
